Clinical Trial Update: A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS [Phase 1]

View source ↗

Summary

Phase 1 safety study of sNN0029 administered via intracerebroventricular route in patients with Amyotrophic Lateral Sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• sNN0029

Snippet

Sponsor: Newron Sweden AB | Conditions: Amyotrophic Lateral Sclerosis | Phase 1 | Status: TERMINATED